Super Bowl Champ Marques Colston on What it Takes to Bring Home the Lombardi Trophy
The Super Bowl is just days away and the Patriots and Eagles are headed into their final days of preparation. Marques Colston, Former NFL Star and Super Bowl champ with the New Orleans Saints, joined us to give us an inside look at what it's like to prepare for the big game.
Colston said players try to keep the routine as natural as possible, but in reality it's nearly impossible. The Patriots have an unmatched level of preparation for the big game. The Saints all-time leader in receiving yards and touchdowns said it definitely gives the Patriots a leg up, but the excitement about making it to the Super Bowl could ultimately be an advantage if the energy is channeled the right way.
Colston is a co-owner of the AFL's Philadelphia Soul. He says it was a natural transition for him because he received advice for life after football while he was still playing. Colston is also on the advisory board for the NFLPA's Tech Accelerator program, which helps players get ready for a new career.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.